Anbio Competitors
| NNNN Stock | 24.66 2.75 12.55% |
Anbio Biotechnology vs Allegion PLC Correlation
Excellent diversification
The correlation between Anbio Biotechnology Class and ALLE is -0.59 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Anbio Biotechnology Class and ALLE in the same portfolio, assuming nothing else is changed.
Moving together with Anbio Stock
| 0.65 | ENTA | Enanta Pharmaceuticals Earnings Call This Week | PairCorr |
Moving against Anbio Stock
At this time, Anbio Biotechnology's Return On Tangible Assets are very stable compared to the past year. As of the 2nd of February 2026, Return On Capital Employed is likely to grow to 0.13, while Return On Equity is likely to drop 0.15. At this time, Anbio Biotechnology's Non Current Assets Total are very stable compared to the past year. As of the 2nd of February 2026, Non Currrent Assets Other is likely to grow to about 467.8 K, while Total Assets are likely to drop about 14.7 M.Anbio Biotechnology Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Anbio Biotechnology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Anbio and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Anbio Biotechnology Class does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Anbio Stock performing well and Anbio Biotechnology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Anbio Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GXRFF | 5.10 | (0.23) | 0.00 | (0.74) | 0.00 | 10.70 | 38.06 | |||
| USSTX | 0.05 | 0.00 | (0.30) | 0.32 | 0.00 | 0.19 | 0.39 | |||
| JDDSF | 0.67 | (0.22) | 0.00 | (0.42) | 0.00 | 0.00 | 22.36 | |||
| NEMTF | 1.04 | (0.51) | 0.00 | 0.45 | 0.00 | 0.00 | 33.70 | |||
| AA | 2.65 | 0.52 | 0.18 | 0.30 | 2.69 | 6.40 | 14.55 | |||
| JDSPY | 2.91 | (0.20) | 0.00 | (0.44) | 0.00 | 6.19 | 15.07 | |||
| ALLE | 0.84 | (0.08) | 0.00 | (0.05) | 0.00 | 2.15 | 5.10 |
Cross Equities Net Income Analysis
Compare Anbio Biotechnology Class and related stocks such as Prospera Energy, Tax Exempt Short, and JD Sports Fashion Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA | (2.3 B) | (2.3 B) | (2.3 B) | (2.3 B) | 268 M | (863 M) | (400 M) | 217 M | 250 M | (1.1 B) | (170 M) | 429 M | (123 M) | (651 M) | 60 M | 1.1 B | 1.2 B |
| ALLE | 218.1 M | 218.1 M | 220.1 M | 32.3 M | 175.2 M | 153.9 M | 229.1 M | 273.3 M | 434.9 M | 401.8 M | 314.3 M | 483 M | 458 M | 540.4 M | 597.5 M | 687.1 M | 356.1 M |
Anbio Biotechnology Class and related stocks such as Prospera Energy, Tax Exempt Short, and JD Sports Fashion Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Anbio Biotechnology Class financial statement analysis. It represents the amount of money remaining after all of Anbio Biotechnology Class operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Anbio Biotechnology Competitive Analysis
The better you understand Anbio Biotechnology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Anbio Biotechnology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Anbio Biotechnology's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Anbio Biotechnology Competition Performance Charts
Five steps to successful analysis of Anbio Biotechnology Competition
Anbio Biotechnology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Anbio Biotechnology Class in relation to its competition. Anbio Biotechnology's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Anbio Biotechnology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Anbio Biotechnology's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Anbio Biotechnology Class, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Anbio Biotechnology position
In addition to having Anbio Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Computers Thematic Idea Now
Computers
Companies that manufacture and distribute personal and business computers. The Computers theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Computers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Anbio Biotechnology Correlation with its peers. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Will Biotechnology sector continue expanding? Could Anbio diversify its offerings? Factors like these will boost the valuation of Anbio Biotechnology. Anticipated expansion of Anbio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Anbio Biotechnology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.028 | Earnings Share 0.06 | Revenue Per Share | Quarterly Revenue Growth (0.22) | Return On Assets |
Understanding Anbio Biotechnology Class requires distinguishing between market price and book value, where the latter reflects Anbio's accounting equity. The concept of intrinsic value—what Anbio Biotechnology's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Anbio Biotechnology's price substantially above or below its fundamental value.
It's important to distinguish between Anbio Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Anbio Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Anbio Biotechnology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.